Free Trial

Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals logo
$284.68 -5.42 (-1.87%)
As of 09:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALNY Latest News

Alnylam Pharmaceuticals, Inc. stock logo
California State Teachers Retirement System Acquires 5,037 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
California State Teachers Retirement System lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,362 shares of the biopharm
Alnylam Pharmaceuticals, Inc. stock logo
Bannerman Wealth Management Group LLC Acquires Shares of 1,391 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Bannerman Wealth Management Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,391 shares of the biopharmaceutical
Alnylam Pharmaceuticals, Inc. stock logo
Voloridge Investment Management LLC Has $3.95 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Voloridge Investment Management LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 91.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,776 shares of the biopharmaceuti
Alnylam Pharmaceuticals, Inc. stock logo
GF Fund Management CO. LTD. Takes $637,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
GF Fund Management CO. LTD. bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,708 shares of the biopharmaceut
Alnylam Pharmaceuticals, Inc. stock logo
Public Employees Retirement System of Ohio Has $10.41 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Public Employees Retirement System of Ohio lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,257 shares of the biopharmaceutical company's stock
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by USS Investment Management Ltd
USS Investment Management Ltd decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,366 shares of the bio
Alnylam Pharmaceuticals, Inc. stock logo
Quantinno Capital Management LP Purchases 1,190 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Quantinno Capital Management LP raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 35.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,556 shares of the biopharmace
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Cetera Investment Advisers
Cetera Investment Advisers increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,770 shares of the biopharma
Alnylam Pharmaceuticals, Inc. stock logo
Two Sigma Advisers LP Has $18.54 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Two Sigma Advisers LP cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 23.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 78,800 shares of the biopharmaceutical company's stock after selling 2
Alnylam Pharmaceuticals, Inc. stock logo
Two Sigma Investments LP Purchases 87,969 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Two Sigma Investments LP grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 459.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 107,117 shares of the biopharmaceutical company's stock after acquiring a
Alnylam Pharmaceuticals, Inc. stock logo
Tidal Investments LLC Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Tidal Investments LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 35.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,188 shares of the biopharmaceutical co
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by ProShare Advisors LLC
ProShare Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,110 shares of th
Alnylam Pharmaceuticals, Inc. stock logo
Worldquant Millennium Advisors LLC Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Worldquant Millennium Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 156.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,191 shares of the biopharmaceutical com
Alnylam Pharmaceuticals, Inc. stock logo
Zurich Insurance Group Ltd FI Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Zurich Insurance Group Ltd FI purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 27,977 shares of the biop
Alnylam Pharmaceuticals, Inc. stock logo
Silvercrest Asset Management Group LLC Purchases Shares of 4,891 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Silvercrest Asset Management Group LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 4,891 shares of the biopharmaceutical compan
Alnylam Pharmaceuticals, Inc. stock logo
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 11,081 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 42.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,731 shares of th
Alnylam Issues 2024 Corporate Responsibility Report
Alnylam Pharmaceuticals, Inc. stock logo
Soleus Capital Management L.P. Acquires 17,400 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Soleus Capital Management L.P. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 29.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,800 shares of the biopharmaceutical company's stock after buying an a
Alnylam Pharmaceuticals, Inc. stock logo
16,323 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Tema Etfs LLC
Tema Etfs LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 16,323 shares of the biopharmaceutical company's s
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Siemens Fonds Invest GmbH
Siemens Fonds Invest GmbH grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 137.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,245 shares of the biopharmaceutical company's stock afte
Alnylam Pharmaceuticals, Inc. stock logo
Focus Partners Wealth Purchases 3,144 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Focus Partners Wealth boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 245.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,427 shares of the biopharmaceutical company's stock afte
Alnylam Pharmaceuticals, Inc. stock logo
Rafferty Asset Management LLC Sells 11,014 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Rafferty Asset Management LLC reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 52,817 shares of the biopharmaceutical company's stock after selling 11,014 shares
Alnylam Pharmaceuticals, Inc. stock logo
OMERS ADMINISTRATION Corp Purchases 891 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
OMERS ADMINISTRATION Corp boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,252 shares of the biopharmaceutical com
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by Gotham Asset Management LLC
Gotham Asset Management LLC decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,924 shares of the biopha
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Graham Capital Management L.P.
Graham Capital Management L.P. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ow
High Growth US Tech Stocks To Watch In May 2025
Alnylam Pharmaceuticals, Inc. stock logo
Parkman Healthcare Partners LLC Has $9.10 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Parkman Healthcare Partners LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,672 shares of the bioph
Alnylam Pharmaceuticals, Inc. stock logo
LMR Partners LLP Has $2.80 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
LMR Partners LLP reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 82.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,901 shares of the biopharmaceutical company's stock after selling 55,588 shares
Alnylam Pharmaceuticals, Inc. stock logo
Janus Henderson Group PLC Sells 9,257 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Janus Henderson Group PLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 210,08
Alnylam Pharmaceuticals, Inc. stock logo
Captrust Financial Advisors Has $1.51 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Captrust Financial Advisors boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,414 shares of the bio
Alnylam Pharmaceuticals, Inc. stock logo
Orbimed Advisors LLC Acquires 165,300 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Orbimed Advisors LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 415,600 shares of the biopharmaceutical comp
Alnylam Pharmaceuticals, Inc. stock logo
Integral Health Asset Management LLC Purchases 20,000 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Integral Health Asset Management LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,000 shares of the biopharmaceutical company's stock
Alnylam Pharmaceuticals, Inc. stock logo
Ensign Peak Advisors Inc Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Ensign Peak Advisors Inc lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,464 shares of the biopharmaceutical compan
Alnylam Pharmaceuticals, Inc. stock logo
2,600 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Mercer Global Advisors Inc. ADV
Mercer Global Advisors Inc. ADV purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,600 shares of the biopharmaceutical
Alnylam Pharmaceuticals, Inc. stock logo
Driehaus Capital Management LLC Acquires 1,130 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Driehaus Capital Management LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,480 shares of the biopharmaceutical company's stock
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold
Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

ALNY Media Mentions By Week

ALNY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALNY
News Sentiment

1.37

0.87

Average
Medical
News Sentiment

ALNY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALNY Articles
This Week

22

15

ALNY Articles
Average Week

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ALNY) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners